Literature DB >> 25248334

Chlorogenic acid improves high fat diet-induced hepatic steatosis and insulin resistance in mice.

Yongjie Ma1, Mingming Gao, Dexi Liu.   

Abstract

PURPOSE: Chlorogenic acid (CGA), the most abundant component in coffee, has exhibited many biological activities. The objective of this study is to assess preventive and therapeutic effects of CGA on obesity and obesity-related liver steatosis and insulin resistance.
METHODS: Two sets of experiments were conducted. In set 1, 6-week old C57BL/6 mice were fed a regular chow or high-fat diet (HFD) for 15 weeks with twice intra-peritoneal (IP) injection of CGA (100 mg/kg) or DMSO (carrier solution) per week. In set 2, obese mice (average 50 g) were treated by CGA (100 mg/kg, IP, twice weekly) or DMSO for 6 weeks. Body weight, body composition and food intake were monitored. Blood glucose, insulin and lipid levels were measured at end of the study. Hepatic lipid accumulation and glucose homeostasis were evaluated. Additionally, genes involved in lipid metabolism and inflammation were analyzed by real time PCR.
RESULTS: CGA significantly blocked the development of diet-induced obesity but did not affect body weight in obese mice. CGA treatment curbed HFD-induced hepatic steatosis and insulin resistance. Quantitative PCR analysis shows that CGA treatment suppressed hepatic expression of Pparγ, Cd36, Fabp4, and Mgat1 gene. CGA treatment also attenuated inflammation in the liver and white adipose tissue accompanied by a decrease in mRNA levels of macrophage marker genes including F4/80, Cd68, Cd11b, Cd11c, and Tnfα, Mcp-1 and Ccr2 encoding inflammatory proteins.
CONCLUSION: Our study provides direct evidence in support of CGA as a potent compound in preventing diet-induced obesity and obesity-related metabolic syndrome. Our results suggest that drinking coffee is beneficial in maintaining metabolic homeostasis when on a high fat diet.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248334      PMCID: PMC4595927          DOI: 10.1007/s11095-014-1526-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

1.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Authors:  María Eugenia Miquilena-Colina; Elena Lima-Cabello; Sonia Sánchez-Campos; María Victoria García-Mediavilla; Miguel Fernández-Bermejo; Tamara Lozano-Rodríguez; Javier Vargas-Castrillón; Xabier Buqué; Begoña Ochoa; Patricia Aspichueta; Javier González-Gallego; Carmelo García-Monzón
Journal:  Gut       Date:  2011-01-26       Impact factor: 23.059

2.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

Authors:  Songtao Yu; Kimihiko Matsusue; Papreddy Kashireddy; Wen-Qing Cao; Vaishalee Yeldandi; Anjana V Yeldandi; M Sambasiva Rao; Frank J Gonzalez; Janardan K Reddy
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

3.  Intraperitoneal injection of clodronate liposomes eliminates visceral adipose macrophages and blocks high-fat diet-induced weight gain and development of insulin resistance.

Authors:  Le Bu; Mingming Gao; Shen Qu; Dexi Liu
Journal:  AAPS J       Date:  2013-07-04       Impact factor: 4.009

4.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

Authors:  Kimihiko Matsusue; Martin Haluzik; Gilles Lambert; Sun-Hee Yim; Oksana Gavrilova; Jerrold M Ward; Bryan Brewer; Marc L Reitman; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

5.  A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk.

Authors:  Mark F McCarty
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

6.  Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy.

Authors:  Víctor A Cortés; David E Curtis; Suja Sukumaran; Xinli Shao; Vinay Parameswara; Shirya Rashid; Amy R Smith; Jimin Ren; Victoria Esser; Robert E Hammer; Anil K Agarwal; Jay D Horton; Abhimanyu Garg
Journal:  Cell Metab       Date:  2009-02       Impact factor: 27.287

Review 7.  Chronic inflammation in obesity and the metabolic syndrome.

Authors:  Rosário Monteiro; Isabel Azevedo
Journal:  Mediators Inflamm       Date:  2010-07-14       Impact factor: 4.711

8.  Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet.

Authors:  Mingming Gao; Yongjie Ma; Ran Cui; Dexi Liu
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

9.  Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.

Authors:  Jie Zhou; Maria Febbraio; Taira Wada; Yonggong Zhai; Ramalinga Kuruba; Jinhan He; Jung Hoon Lee; Shaheen Khadem; Songrong Ren; Song Li; Roy L Silverstein; Wen Xie
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

10.  Rutin suppresses palmitic acids-triggered inflammation in macrophages and blocks high fat diet-induced obesity and fatty liver in mice.

Authors:  Mingming Gao; Yongjie Ma; Dexi Liu
Journal:  Pharm Res       Date:  2013-06-20       Impact factor: 4.200

View more
  43 in total

1.  Phloretin Prevents High-Fat Diet-Induced Obesity and Improves Metabolic Homeostasis.

Authors:  Sary Alsanea; Mingming Gao; Dexi Liu
Journal:  AAPS J       Date:  2017-02-14       Impact factor: 4.009

2.  N-acetylcysteine Protects Mice from High Fat Diet-induced Metabolic Disorders.

Authors:  Yongjie Ma; Mingming Gao; Dexi Liu
Journal:  Pharm Res       Date:  2016-05-09       Impact factor: 4.200

3.  BITC and S-Carvone Restrain High-Fat Diet-Induced Obesity and Ameliorate Hepatic Steatosis and Insulin Resistance.

Authors:  Sary Alsanea; Dexi Liu
Journal:  Pharm Res       Date:  2017-07-21       Impact factor: 4.200

Review 4.  Mechanisms of action of coffee bioactive components on lipid metabolism.

Authors:  Renalison Farias-Pereira; Cheon-Seok Park; Yeonhwa Park
Journal:  Food Sci Biotechnol       Date:  2019-08-12       Impact factor: 2.391

5.  Dietary walnut reduces hepatic triglyceride content in high-fat-fed mice via modulation of hepatic fatty acid metabolism and adipose tissue inflammation.

Authors:  Youngshim Choi; Mohamed A Abdelmegeed; Mohammed Akbar; Byoung-Joon Song
Journal:  J Nutr Biochem       Date:  2016-01-06       Impact factor: 6.048

6.  Chlorogenic acid alleviates autophagy and insulin resistance by suppressing JNK pathway in a rat model of nonalcoholic fatty liver disease.

Authors:  Hua Yan; Yan-Qiong Gao; Ying Zhang; Huan Wang; Gui-Sheng Liu; Jian-Yuan Lei
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

7.  Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake.

Authors:  Saritha Krishna; Zhoumeng Lin; Claire B de La Serre; John J Wagner; Donald H Harn; Lacey M Pepples; Dylan M Djani; Matthew T Weber; Leena Srivastava; Nikolay M Filipov
Journal:  Physiol Behav       Date:  2016-02-04

8.  Dietary chlorogenic acid improves growth performance of weaned pigs through maintaining antioxidant capacity and intestinal digestion and absorption function.

Authors:  Jiali Chen; Yan Li; Bing Yu; Daiwen Chen; Xiangbing Mao; Ping Zheng; Junqiu Luo; Jun He
Journal:  J Anim Sci       Date:  2018-04-03       Impact factor: 3.159

Review 9.  The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literature.

Authors:  Narges Tajik; Mahboubeh Tajik; Isabelle Mack; Paul Enck
Journal:  Eur J Nutr       Date:  2017-04-08       Impact factor: 5.614

Review 10.  The effect of green coffee extract supplementation on cardio metabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Mehrnaz Morvaridi; Elham Rayyani; Malihe Jaafari; Alireza Khiabani; Mehran Rahimlou
Journal:  J Diabetes Metab Disord       Date:  2020-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.